Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research note published on Monday morning,Benzinga reports.

Several other equities analysts also recently weighed in on GOSS. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Finally, Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Stock Performance

Shares of GOSS opened at $10.69 on Monday. Gossamer Bio has a fifty-two week low of $8.29 and a fifty-two week high of $309.60. The stock has a market capitalization of $65.32 million, a PE ratio of -0.19 and a beta of 2.21. The company’s fifty day moving average is $11.34 and its 200 day moving average is $44.87.

Hedge Funds Weigh In On Gossamer Bio

A number of institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC purchased a new position in shares of Gossamer Bio during the second quarter worth $35,000. Hsbc Holdings PLC acquired a new position in Gossamer Bio in the 1st quarter worth about $38,000. SG Americas Securities LLC raised its stake in shares of Gossamer Bio by 73.4% during the 1st quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock worth $42,000 after buying an additional 54,439 shares during the period. Bank of America Corp DE purchased a new position in Gossamer Bio during the second quarter valued at $65,000. Finally, Ieq Capital LLC purchased a new position in Gossamer Bio in the 2nd quarter valued at about $97,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.